975 related articles for article (PubMed ID: 25053345)
1. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
Corcoran C; Rani S; O'Driscoll L
Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
[TBL] [Abstract][Full Text] [Related]
2. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
3. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1.
Zhang G; Tian X; Li Y; Wang Z; Li X; Zhu C
Biomed Pharmacother; 2018 Jan; 97():736-744. PubMed ID: 29102917
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.
Kharaziha P; Chioureas D; Rutishauser D; Baltatzis G; Lennartsson L; Fonseca P; Azimi A; Hultenby K; Zubarev R; Ullén A; Yachnin J; Nilsson S; Panaretakis T
Oncotarget; 2015 Aug; 6(25):21740-54. PubMed ID: 25844599
[TBL] [Abstract][Full Text] [Related]
5. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.
Kojima K; Fujita Y; Nozawa Y; Deguchi T; Ito M
Prostate; 2010 Oct; 70(14):1501-12. PubMed ID: 20687223
[TBL] [Abstract][Full Text] [Related]
6. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
[TBL] [Abstract][Full Text] [Related]
7. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
8. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells.
Fujita Y; Kojima K; Hamada N; Ohhashi R; Akao Y; Nozawa Y; Deguchi T; Ito M
Biochem Biophys Res Commun; 2008 Dec; 377(1):114-9. PubMed ID: 18834855
[TBL] [Abstract][Full Text] [Related]
9. Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis: Application for prostate cancer diagnostic.
Samsonov R; Shtam T; Burdakov V; Glotov A; Tsyrlina E; Berstein L; Nosov A; Evtushenko V; Filatov M; Malek A
Prostate; 2016 Jan; 76(1):68-79. PubMed ID: 26417675
[TBL] [Abstract][Full Text] [Related]
10. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.
O'Brien K; Lowry MC; Corcoran C; Martinez VG; Daly M; Rani S; Gallagher WM; Radomski MW; MacLeod RA; O'Driscoll L
Oncotarget; 2015 Oct; 6(32):32774-89. PubMed ID: 26416415
[TBL] [Abstract][Full Text] [Related]
11. miRNAs dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways.
Lichner Z; Ding Q; Samaan S; Saleh C; Nasser A; Al-Haddad S; Samuel JN; Fleshner NE; Stephan C; Jung K; Yousef GM
J Pathol; 2015 Oct; 237(2):226-37. PubMed ID: 26011734
[TBL] [Abstract][Full Text] [Related]
12. The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance.
Bascetta L; Oliviero A; D'Aurizio R; Evangelista M; Mercatanti A; Pellegrini M; Marrocolo F; Bracarda S; Rizzo M
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703747
[TBL] [Abstract][Full Text] [Related]
13. β-Elemene Reverses Chemoresistance of Breast Cancer Cells by Reducing Resistance Transmission via Exosomes.
Zhang J; Zhang HD; Yao YF; Zhong SL; Zhao JH; Tang JH
Cell Physiol Biochem; 2015; 36(6):2274-86. PubMed ID: 26279432
[TBL] [Abstract][Full Text] [Related]
14. Exosome-derived miRNAs and ovarian carcinoma progression.
Vaksman O; Tropé C; Davidson B; Reich R
Carcinogenesis; 2014 Sep; 35(9):2113-20. PubMed ID: 24925027
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.
Corcoran C; Rani S; O'Brien K; O'Neill A; Prencipe M; Sheikh R; Webb G; McDermott R; Watson W; Crown J; O'Driscoll L
PLoS One; 2012; 7(12):e50999. PubMed ID: 23251413
[TBL] [Abstract][Full Text] [Related]
16. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1.
Feng B; Wang R; Chen LB
Cancer Lett; 2012 Apr; 317(2):184-91. PubMed ID: 22120675
[TBL] [Abstract][Full Text] [Related]
17. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs.
Chen WX; Liu XM; Lv MM; Chen L; Zhao JH; Zhong SL; Ji MH; Hu Q; Luo Z; Wu JZ; Tang JH
PLoS One; 2014; 9(4):e95240. PubMed ID: 24740415
[TBL] [Abstract][Full Text] [Related]
18. LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p.
Jiang X; Guo S; Zhang Y; Zhao Y; Li X; Jia Y; Xu Y; Ma B
Cell Signal; 2020 Jan; 65():109422. PubMed ID: 31672604
[TBL] [Abstract][Full Text] [Related]
19. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2.
Qiu T; Zhou L; Wang T; Xu J; Wang J; Chen W; Zhou X; Huang Z; Zhu W; Shu Y; Liu P
Int J Mol Med; 2013 Sep; 32(3):593-8. PubMed ID: 23856992
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
